Search | Clinical Trials Finder

Conditions: Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more

Conditions: Breast Cancer
Interventions: Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Invasive Breast Cancer
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 4,385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Lobular Breast Carcinoma
Interventions: [68Ga]Ga DOTA-5G; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer
Interventions: capecitabine [Xeloda], Taxotere, Herceptin (HER2-neu positive patients only); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 38
States / cities: Los Angeles, California • Montebello, California • Palm Springs, California + 30 more

Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery; Procedure · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Breast Cancer, Ductal Carcinoma
Interventions: Nipple-Sparing Mastectomy, Breast Reconstruction, Axillary Surgery, Prophylactic Nipple-Areolar Complex RT; Procedure · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: FNA and Core biopsy; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Ductal Carcinoma in Situ, Breast Cancer
Interventions: Novel cavity marking technique; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 88
States / cities: Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more

Conditions: Primary Invasive Breast Cancer
Interventions: Observational; Other
Lead sponsor: Myriad Genetic Laboratories, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 52
States / cities: Burbank, California • Roseville, California • Fort Myers, Florida + 40 more

Conditions: Breast Cancer
Interventions: Lumpectomy without sentinel node biopsy; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Axillary Nodal Disease, Female Breast Cancer, Axilla; Breast, Mastectomy; Lymphedema, Tumor, Breast
Interventions: Breast Surgery (BCS or mastectomy) with TAD/SNB, Adjuvant Radiation Therapy; Procedure · Radiation
Lead sponsor: Alice Chung; Other
Eligibility: 45 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 3
States / cities: Los Angeles, California • Pasadena, California • Tarzana, California

Conditions: Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
Interventions: Standard of Care Schedule Variation: SABR, Breast-conserving Surgery; Other · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment; Genetic · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 20 Years and older · Female only
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 3
States / cities: Beverly Hills, California • Duarte, California • Pasadena, California

Conditions: Neoplasms, Breast
Interventions: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Astrocytoma, Breast Carcinoma Metastatic in the Brain, Glioma, Invasive Breast Carcinoma, Oligodendroglioma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Glioma
Interventions: Best Practice, Ketoconazole; Other · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer
Interventions: magnetic resonance thermal imaging, laser interstitial thermal therapy; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: mammography; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 311
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more

Conditions: Invasive Breast Cancer
Interventions: Eucerin, Mometasone Furoate 0.1%; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Depression, Breast Cancer, Stress, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions: Videoconferencing support group; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Genetic Testing
Interventions: Standard Genetic Counseling, Quantitative Genetic Counseling; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Skin Reactions Secondary to Radiation Therapy
Interventions: adjuvant therapy, conventional surgery, 3-dimensional conformal radiation therapy, brachytherapy, intracavitary balloon brachytherapy, proton beam radiation therapy; Procedure · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction

Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

EndoPredict® Extended Endocrine Trial (EXET)

Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

Expanding Rural Access: Distance Delivery of Support Groups (Main Study)

Genetic Testing for All Breast Cancer Patients (GET FACTS)

Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer